Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 5/20 | 0.36 |
| ▸ | GSK3B | P49841 | 14/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 14/20 | 0.35 |
| ▸ | WNT1 | P04628 | 8/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | CLK3 | P49761 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25085265 | 0.89 | TGFBR1 (0.37) | TGFBR1GSK3BDYRK1AMAPK14 | |
| SCHEMBL25084878 | 0.88 | TGFBR1 (0.43) | TGFBR1GSK3BDYRK1AWNT1 | |
| SCHEMBL30156122 | 0.88 | TGFBR1 (0.43) | TGFBR1GSK3BDYRK1AWNT1 | |
| SCHEMBL22075215 | 0.87 | SCN9A (0.39) | GSK3BDYRK1AWNT1CLK2CLK3 | |
| SCHEMBL25084540 | 0.87 | TGFBR1 (0.39) | TGFBR1MAPK14 | |
| SCHEMBL30156191 | 0.87 | TGFBR1 (0.39) | TGFBR1MAPK14 | |
| SCHEMBL25084854 | 0.86 | TGFBR1 (0.37) | TGFBR1MAPK14 | |
| SCHEMBL25085115 | 0.85 | PDCD1 (0.38) | TGFBR1MAPK14 | |
| SCHEMBL25084666 | 0.85 | PDCD1 (0.38) | TGFBR1MAPK14 | |
| SCHEMBL22075108 | 0.85 | GSK3B (0.35) | GSK3BDYRK1AWNT1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | TGFBR1 211/4885GSK3B 624/4885DYRK1A 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.